Zealand Pharma A/S (CPH:ZEAL)
Denmark · Delayed Price · Currency is DKK 312.90
-4.10 (-1.29%)
Aug 28, 2026, 4:59 PM CET
Zealand Pharma Income Statement
Financials in millions DKK. Fiscal year is January - December.
Millions DKK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,644 | 9,215 | 62.69 | 342.79 | 103.99 | 108.55 | |
Revenue Growth | -49.02% | 14598.86% | -81.71% | 229.65% | -4.20% | -43.47% |
Cost of Revenue | -0.18 | 0.82 | 7.87 | 3.2 | - | 10.97 |
Gross Profit | 4,644 | 9,214 | 54.82 | 339.59 | 103.99 | 97.58 |
Selling, General & Admin | 500.95 | 495.95 | 404.02 | 215.93 | 269.51 | 298.21 |
Research & Development | 1,836 | 1,605 | 919.87 | 684.9 | 614.04 | 581.51 |
Other Operating Expenses | 0.42 | 196.42 | - | - | 48.27 | - |
Operating Expenses | 2,337 | 2,297 | 1,324 | 900.83 | 920.59 | 879.72 |
Operating Income | 2,307 | 6,917 | -1,269 | -561.24 | -816.6 | -782.14 |
Interest Expense | -27.06 | -29.06 | -34.05 | -25.83 | -57.79 | -4.09 |
Interest & Investment Income | 357.34 | 309.34 | 169.64 | 45.32 | 6.54 | 0.04 |
Currency Exchange Gain (Loss) | 205.91 | -295.1 | 18.29 | -9.71 | 25.6 | 36.52 |
Other Non Operating Income (Expenses) | -92.27 | 8.73 | -17.46 | -1.99 | 11.01 | -3.47 |
EBT Excluding Unusual Items | 2,751 | 6,911 | -1,133 | -553.44 | -831.24 | -753.14 |
Merger & Restructuring Charges | - | - | - | - | -19.1 | - |
Gain (Loss) on Sale of Investments | 46.71 | 47.71 | 52.34 | -8.84 | 2.34 | -3.57 |
Asset Writedown | - | - | - | -11 | -1.46 | -2.17 |
Legal Settlements | - | - | -3.14 | - | - | - |
Other Unusual Items | 42.34 | 42.34 | - | -135.59 | -122.58 | - |
Pretax Income | 2,840 | 7,001 | -1,083 | -708.87 | -972.04 | -758.89 |
Income Tax Expense | 99.06 | 546.06 | -4.62 | -5.13 | -6.43 | -3.95 |
Earnings From Continuing Operations | 2,741 | 6,455 | -1,079 | -703.74 | -965.61 | -754.94 |
Earnings From Discontinued Operations | - | - | - | - | -236.53 | -263.21 |
Net Income | 2,741 | 6,455 | -1,079 | -703.74 | -1,202 | -1,018 |
Net Income to Common | 2,741 | 6,455 | -1,079 | -703.74 | -1,202 | -1,018 |
Net Income Growth | -58.97% | - | - | - | - | - |
Shares Outstanding (Basic) | 70 | 71 | 66 | 57 | 46 | 43 |
Shares Outstanding (Diluted) | 71 | 72 | 66 | 57 | 46 | 43 |
Shares Change | -0.27% | 7.70% | 17.40% | 22.49% | 7.77% | 11.73% |
EPS (Basic) | 38.94 | 91.56 | -16.24 | -12.44 | -26.02 | -23.75 |
EPS (Diluted) | 38.53 | 90.22 | -16.24 | -12.44 | -26.02 | -23.75 |
EPS Growth | -58.86% | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1,796 | 6,499 | -940.87 | -436.91 | -954.02 | -1,234 |
Free Cash Flow Per Share | -25.26 | 90.83 | -14.16 | -7.72 | -20.65 | -28.79 |
Gross Margin | 100.00% | 99.99% | 87.44% | 99.07% | 100.00% | 89.89% |
Operating Margin | 49.68% | 75.06% | -2024.33% | -163.73% | -785.30% | -720.57% |
Profit Margin | 59.02% | 70.05% | -1720.87% | -205.30% | -1156.05% | -937.99% |
Free Cash Flow Margin | -38.68% | 70.52% | -1500.80% | -127.46% | -917.45% | -1136.94% |
EBITDA | 2,324 | 6,927 | -1,258 | -554.7 | -729.52 | -768.57 |
EBITDA Margin | 50.05% | 75.17% | - | -161.82% | - | - |
D&A For EBITDA | 16.95 | 9.95 | 10.58 | 6.54 | 87.08 | 13.57 |
EBIT | 2,307 | 6,917 | -1,269 | -561.24 | -816.6 | -782.14 |
EBIT Margin | 49.68% | 75.06% | - | -163.73% | - | - |
Effective Tax Rate | 3.49% | 7.80% | - | - | - | - |